Reason
48Agents and models that generate hypotheses, plans, code, protocols, papers, or scientific arguments.
Open research
The AI for Science
Landscape.
A source-backed data hub for the companies, labs, benchmarks, and market signals pushing science toward autonomous discovery. Science-first AGI progress, tracked where it changes research workflows.
Capabilities & AGI progress
Measured by the
time horizon.
AGI progress reads cleanest as the length of work AI can finish on its own — now ~16 hours of expert work at 50% reliability, doubling every few months.
The full exponential, the 4-of-6 human-baseline crossings, and the recursive-self-improvement ledger live on a dedicated page.
Task horizon
16 h
At 50% reliability · doubling ~4-5 months.
AI vs human-expert baseline
MMLU92%
GPQA Diamond94%
MATH-50097%
OSWorld75%
ARC-AGI-285%
Market snapshot
From landscape
to data hub.
The field is no longer a loose list of AI labs and automation vendors. It is splitting into a stack: reasoning engines, experimental execution layers, verification systems, proprietary data loops, and institutional infrastructure.
This release keeps the editorial map, but adds comparable dimensions and source-backed records so the page can evolve into a benchmark institute rather than a static directory.
Entities
67
Company funding
32
Ecosystem events
12
Milestones
166
Sources
314
Capital signals
US$ millions by yearIncludes closed company rounds plus ecosystem capital with explicit committed amounts. Biobucks deal value, program ceilings (FOAs and open calls), adjacent physical-AI signals, talks, and valuation-only events stay out of totals.
Autonomy stack coverage
63 science domainsA single entity can occupy multiple roles. Full-stack labs count across reason, execute, verify, and data where the public record supports it.
Geography and stage
DistributionRegion
North America48
Europe14
Asia-Pacific3
North America / Europe1
North America / Middle East1
Stage
Growth10
Private scaleup8
Seed8
Commercial8
Research facility8
Public5
Series A4
Research platform2
Dimensional scorecard
Average, 0-4Autonomy
2.6
Execution
2.6
Verification
2.6
Scientific evidence
2.9
Capital
2.7
Traction
2.9
Scores are dimensions, not a ranking. They make tradeoffs legible before a future Scivity index exists.
Autonomy stack
Where each player
actually sits.
The useful comparison is not “AI company versus lab automation company.” It is which part of the scientific method each system can own, and which parts still depend on people or external infrastructure.
Execute
44Physical and remote systems that turn plans into experiments, synthesis runs, assays, or lab workflows.
Verify
49Evaluation, replication, critique, measurement, and validation layers that determine whether a claim survives contact with reality.
Data
56Platforms that generate, structure, or own proprietary scientific data loops unavailable on the open web.
Infrastructure
30Cloud labs, national facilities, robotics stacks, orchestration software, and institutional programs that make autonomous science deployable.
Entity explorer
Compare the field
without collapsing it.
Filter by stack role, domain, organization type, evidence level, capital band, and access model. Select up to four entities for a side-by-side comparison.
Sort
67 shown
Select up to four entities to compare dimensional scores, stack roles, evidence level, and access model.
01
Public company
Ginkgo Bioworks
Public · North America · Boston, MA · Founded 2008 · Updated 2026-05
Public deployment12NYSE: DNACIK 0001830214Public companyHybrid
Synthetic biology foundry. Engineered organisms as a service; increasingly AI-augmented across the design-build-test-learn cycle.
Cash + securities
$373M
$144M cash / $230M securities
Runway
9.2 mo
$47M burn / qtr
Research
3 outputs
1 measured results
Clinical
0 trials
No registry link
Non-dilutive
1 award
$47M
Deals
3 deals
ProQR Therapeutics
Sources
20
linked evidence records
Autonomy
3Execution
4Verification
3Scientific evidence
4Capital
3Traction
4ReasonExecuteDataInfrastructureBiologySynthetic biologyCloud lab
02
Public company
AbCellera
Public · North America · Vancouver, Canada · Founded 2012 · Updated 2026-02
Public deployment5Nasdaq: ABCLCIK 0001703057Public companyPartnership platform
Public antibody-discovery platform company. Integrates single-cell screening, computation, antibody engineering, translational science, and clinical manufacturing from target to clinic.
Cash & equivalents
$129M
FY 2025 10-K
Runway
11.7 mo
$33M burn / qtr
Research
1 output
Public company
Clinical
1 trial
Phase 1
Non-dilutive
0 awards
No tracked grants
Deals
1 deal
Eli Lilly
Sources
13
linked evidence records
Autonomy
2Execution
4Verification
3Scientific evidence
4Capital
4Traction
4ReasonExecuteDataVerifyBiologyAntibody discoveryClinical manufacturing
03
Company
Periodic Labs
Private scaleup · North America · San Francisco, CA · Founded 2025 · Updated 2026-05
Working prototype2Announced platformProprietary
Autonomous physical labs for materials and chemistry. AI scientists generate hypotheses; robotic labs run synthesis and characterization; results feed back as training data unavailable anywhere else.
Capital
$300M
Secondary / new round · Mar 2026
Runway
Not public
No public cash ledger
Research
1 output
Announced platform
Clinical
0 trials
No registry link
Non-dilutive
0 awards
No tracked grants
Deals
0 deals
No tracked partnerships
Sources
10
linked evidence records
Autonomy
4Execution
4Verification
3Scientific evidence
3Capital
4Traction
2ReasonExecuteDataVerifyMaterialsChemistry
04
Company
Lila Sciences
Private scaleup · North America · Cambridge, MA · Founded 2023 · Updated 2026-05
Working prototype1Announced platformProprietary
AI Science Factories — integrated reasoning models, robotic labs, and verifiers running the scientific method across life, chemistry, and materials sciences.
Capital
$550M
Series A · Sep 2025
Runway
Not public
No public cash ledger
Research
1 output
Announced platform
Clinical
0 trials
No registry link
Non-dilutive
0 awards
No tracked grants
Deals
0 deals
No tracked partnerships
Sources
9
linked evidence records
Autonomy
4Execution
4Verification
3Scientific evidence
3Capital
4Traction
2ReasonExecuteVerifyDataBiologyChemistryMaterials
05
Company
Chemify
Growth · Europe · Glasgow, UK · Founded 2023 · Updated 2026-04
Published results5Published platformProprietary
Chemputer platform — universal chemical synthesis via programmable hardware and AI-driven reaction planning. Commercialization of Lee Cronin's Glasgow work.
Capital
$50M
Series B · Oct 2025
Runway
Not public
No public cash ledger
Research
3 outputs
Published platform
Clinical
0 trials
No registry link
Non-dilutive
0 awards
No tracked grants
Deals
0 deals
No tracked partnerships
Sources
13
linked evidence records
Autonomy
3Execution
4Verification
3Scientific evidence
4Capital
3Traction
3ReasonExecuteVerifyInfrastructureChemistryDrug discoveryProgrammable synthesis
06
Public company
Recursion Pharmaceuticals
Public · North America · Salt Lake City, UT · Founded 2013 · Updated 2026-05
Public deployment8Nasdaq: RXRXCIK 0001601830Public companyProprietary
Publicly traded AI-native drug discovery platform. Industrial-scale phenomics, ML-driven target identification, and image-based screening at PB-scale.
Cash & equivalents
$654M
Q1 2026 10-Q
Runway
24.2 mo
$81M burn / qtr
Research
3 outputs
Public company
Clinical
1 trial
Phase 1b/2
Non-dilutive
0 awards
No tracked grants
Deals
0 deals
No tracked partnerships
Sources
16
linked evidence records
Autonomy
2Execution
3Verification
3Scientific evidence
4Capital
4Traction
4ReasonExecuteDataVerifyBiologyDrug discoveryImaging
07
Government lab
Argonne National Laboratory
Research facility · North America · Lemont, IL · Founded 1946 · Updated 2026-05
Published results3Research facilityPublic infrastructure
DOE national lab with an explicit Autonomous Discovery initiative. Uses AI, robotics, simulations, data platforms, and self-driving chemistry tools to automate experiments and scientific decision loops.
Capital
Government
Undisclosed / other
Runway
Not public
No public cash ledger
Research
1 output
Research facility
Clinical
0 trials
No registry link
Non-dilutive
1 award
$3M
Deals
0 deals
No tracked partnerships
Sources
11
linked evidence records
Autonomy
4Execution
4Verification
3Scientific evidence
4Capital
2Traction
3ReasonExecuteInfrastructureDataVerifyMaterialsChemistryBiologyEnergy
08
Government lab
Oak Ridge National Laboratory
Research facility · North America · Oak Ridge, TN · Founded 1943 · Updated 2026-05
Published results2Research facilityPublic infrastructure
DOE national lab building autonomous science platforms across instrumentation, computing, and laboratory automation. INTERSECT and the Autonomous Chemistry Lab connect AI, robotics, and HPC.
Capital
Government
Undisclosed / other
Runway
Not public
No public cash ledger
Research
1 output
Research facility
Clinical
0 trials
No registry link
Non-dilutive
0 awards
No tracked grants
Deals
0 deals
No tracked partnerships
Sources
10
linked evidence records
Autonomy
4Execution
4Verification
3Scientific evidence
4Capital
2Traction
3ReasonExecuteInfrastructureDataVerifyMaterialsChemistryEnergyComputing
09
Government lab
NIST
Research facility · North America · Gaithersburg, MD · Founded 1901 · Updated 2026-05
Published results4Research facilityPublic infrastructure
US standards and measurement institute with autonomous-laboratory programs in materials, formulations, metrology, and biofoundry automation. Focuses on closed-loop experimentation and interoperability.
Capital
Government
Undisclosed / other
Runway
Not public
No public cash ledger
Research
2 outputs
Research facility
Clinical
0 trials
No registry link
Non-dilutive
0 awards
No tracked grants
Deals
0 deals
No tracked partnerships
Sources
13
linked evidence records
Autonomy
3Execution
4Verification
4Scientific evidence
4Capital
2Traction
3ExecuteVerifyInfrastructureDataMaterialsMetrologyFormulationsBiology
10
Government lab
A-Lab (LBNL)
Research facility · North America · Berkeley, CA · Founded 2022 · Updated 2026-02
Published results3Published platformPublic infrastructure
Autonomous materials synthesis lab at Lawrence Berkeley National Lab. AI-driven synthesis of novel inorganic materials.
Capital
Government
Undisclosed / other
Runway
Not public
No public cash ledger
Research
1 output
1 correction event
Clinical
0 trials
No registry link
Non-dilutive
0 awards
No tracked grants
Deals
0 deals
No tracked partnerships
Sources
11
linked evidence records
Autonomy
4Execution
4Verification
2Scientific evidence
4Capital
2Traction
3ReasonExecuteVerifyDataMaterialsChemistry
11
Frontier AI lab
Google DeepMind
Big Tech lab · Europe · London, UK · Founded 2010 · Updated 2026-05
Published results20Frontier researchHybrid
AlphaFold, AlphaProteo, GNoME, AlphaGeometry, AlphaEvolve — state-of-the-art scientific AI, without a dedicated autonomous-lab product line.
Capital
Alphabet subsidiary
Undisclosed / other
Runway
Not public
No public cash ledger
Research
9 outputs
10 measured results
Clinical
0 trials
No registry link
Non-dilutive
0 awards
No tracked grants
Deals
0 deals
No tracked partnerships
Sources
26
linked evidence records
Autonomy
3Execution
1Verification
3Scientific evidence
4Capital
4Traction
4ReasonVerifyDataBiologyMaterialsMathematicsGeneral science
12
Public company
Insilico Medicine
Public · Asia-Pacific · Hong Kong (also Boston, New York) · Founded 2014 · Updated 2026-03
Working prototype6HKEX: 03696.HKClinical dataProprietary
End-to-end generative AI platform for drug discovery and development (Pharma.AI). Public on the Hong Kong Stock Exchange since December 2025. TNIK inhibitor rentosertib is the first AI-discovered and AI-designed drug to deliver Phase 2a clinical data.
Capital
Public (HKG: 03696.HK)
Public
Runway
Pending
Non-SEC public company; HKEX financial statements are not yet normalized into public-financials.json.
Research
1 output
Clinical data
Clinical
1 trial
Phase 2a
Non-dilutive
0 awards
No tracked grants
Deals
1 deal
Eli Lilly
Sources
14
linked evidence records
Autonomy
2Execution
2Verification
3Scientific evidence
4Capital
4Traction
4ReasonVerifyDataBiologyDrug discoveryClinical development
13
Government lab
NREL
Research facility · North America · Golden, CO · Founded 1977 · Updated 2024-10
Published results2Research facilityPublic infrastructure
DOE national lab with autonomous experimentation capabilities for energy materials. Work includes autonomous synthesis, autonomous characterization, and AI-assisted control software for instruments.
Capital
Government
Undisclosed / other
Runway
Not public
No public cash ledger
Research
2 outputs
Research facility
Clinical
0 trials
No registry link
Non-dilutive
0 awards
No tracked grants
Deals
0 deals
No tracked partnerships
Sources
10
linked evidence records
Autonomy
3Execution
4Verification
3Scientific evidence
4Capital
2Traction
3ExecuteDataVerifyInfrastructureMaterialsEnergyCharacterization
14
Government lab
Brookhaven National Laboratory
Research facility · North America · Upton, NY · Founded 1947 · Updated 2023-01
Published results4Research facilityPublic infrastructure
DOE national lab and user-facility operator applying AI, robotics, and autonomous experiment steering to materials and photon-science workflows at NSLS-II and CFN.
Capital
Government
Undisclosed / other
Runway
Not public
No public cash ledger
Research
1 output
Research facility
Clinical
0 trials
No registry link
Non-dilutive
0 awards
No tracked grants
Deals
0 deals
No tracked partnerships
Sources
12
linked evidence records
Autonomy
3Execution
4Verification
3Scientific evidence
4Capital
2Traction
3ExecuteDataVerifyInfrastructureMaterialsPhoton scienceNanoscience
15
Company
Chai Discovery
Growth · North America · San Francisco, CA · Founded 2024 · Updated 2026-01
Working prototype6Wet-lab validated modelCommercial partnership
AI drug and biologics design company building a computer-aided design suite for molecules, with Chai-2 focused on zero-shot antibody and protein-binder design.
Capital
$130M
Series B · Dec 2025
Runway
Not public
No public cash ledger
Research
1 output
Wet-lab validated model
Clinical
0 trials
No registry link
Non-dilutive
0 awards
No tracked grants
Deals
1 deal
Eli Lilly
Sources
14
linked evidence records
Autonomy
3Execution
1Verification
3Scientific evidence
4Capital
4Traction
4ReasonDataVerifyBiologyDrug discoveryProtein design
16
Company
Profluent
Growth · North America · Berkeley, CA · Founded 2022 · Updated 2026-05
Working prototype4Wet-lab validated modelHybrid
Programmable-biology company using frontier protein language models. November 2025 closed a $106M Series B co-led by Altimeter Capital and Bezos Expeditions, taking total funding to $150M. May 2026 announced a strategic collaboration with Eli Lilly for custom site-specific recombinases addressing severe-unmet-need diseases, with up to $2.25B in development and commercial milestones plus tiered royalties. Released OpenCRISPR-1, the first AI-generated CRISPR gene editor.
Capital
$106M
Series B · Nov 2025
Runway
Not public
No public cash ledger
Research
0 outputs
Wet-lab validated model
Clinical
0 trials
No registry link
Non-dilutive
0 awards
No tracked grants
Deals
1 deal
Eli Lilly
Sources
12
linked evidence records
Autonomy
2Execution
2Verification
3Scientific evidence
4Capital
4Traction
4ReasonDataVerifyBiologyProtein designGene editing
17
Company
Emerald Cloud Lab
Commercial · North America · South San Francisco, CA · Founded 2010 · Updated 2025-10
Public deployment2CommercialProprietary
Remote-controlled cloud lab — programmable chemistry and biology infrastructure accessed via a full scientific-computing environment.
Capital
Private, undisclosed
Undisclosed / other
Runway
Not public
No public cash ledger
Research
1 output
Commercial
Clinical
0 trials
No registry link
Non-dilutive
0 awards
No tracked grants
Deals
0 deals
No tracked partnerships
Sources
11
linked evidence records
Autonomy
2Execution
4Verification
3Scientific evidence
3Capital
2Traction
4ExecuteInfrastructureDataVerifyChemistryBiologyCloud lab
18
Academic network
Acceleration Consortium
Research network · North America · Toronto, Canada · Founded 2021 · Updated 2025-04
Published results3Research networkPublic infrastructure
International consortium based at University of Toronto. Coordinates self-driving labs across member institutions; publishes protocols and standards.
Capital
$200M+ (CFREF grant)
$100M-$499M
Runway
Not public
No public cash ledger
Research
2 outputs
Research network
Clinical
0 trials
No registry link
Non-dilutive
0 awards
No tracked grants
Deals
0 deals
No tracked partnerships
Sources
12
linked evidence records
Autonomy
2Execution
3Verification
3Scientific evidence
4Capital
3Traction
3ExecuteVerifyInfrastructureDataMaterialsChemistryStandards
19
Frontier AI lab
OpenAI
Frontier platform · North America · San Francisco, CA · Founded 2015 · Updated 2026-05
Working prototype21Frontier platformProprietary
Frontier model developer. April 2026 Industrial Policy paper explicitly calls for distributed AI-enabled laboratories as public infrastructure.
Capital
$40B+ raised
$500M+
Runway
Not public
No public cash ledger
Research
3 outputs
14 measured results
Clinical
0 trials
No registry link
Non-dilutive
0 awards
No tracked grants
Deals
0 deals
No tracked partnerships
Sources
25
linked evidence records
Autonomy
3Execution
1Verification
3Scientific evidence
3Capital
4Traction
4ReasonVerifyInfrastructureGeneral scienceBiologyReasoning
20
Company
Isomorphic Labs
Private scaleup · Europe · London, UK · Founded 2021 · Updated 2026-04
Working prototype4Clinical pipelineProprietary
Alphabet-backed AI drug discovery company spun out of Google DeepMind. Builds on AlphaFold to design novel therapeutics, with a 17-program pipeline advancing toward the clinic.
Capital
$600M
First external round · Apr 2025
Runway
Not public
No public cash ledger
Research
1 output
Clinical pipeline
Clinical
0 trials
No registry link
Non-dilutive
0 awards
No tracked grants
Deals
2 deals
Eli Lilly
Sources
12
linked evidence records
Autonomy
2Execution
2Verification
3Scientific evidence
4Capital
4Traction
3ReasonVerifyDataBiologyDrug discovery
21
Company
Generate Biomedicines
Clinical-stage platform · North America · Somerville, MA · Founded 2018 · Updated 2026-01
Working prototype8Clinical pipelineProprietary
Generative biology company creating programmable protein therapeutics. Combines machine-learning design with biological engineering and high-throughput wet-lab validation to build a clinical pipeline.
Capital
$643M
Series C · Sep 2023
Runway
Not public
No public cash ledger
Research
1 output
Clinical pipeline
Clinical
1 trial
Phase 3
Non-dilutive
0 awards
No tracked grants
Deals
1 deal
Amgen
Sources
16
linked evidence records
Autonomy
2Execution
3Verification
3Scientific evidence
3Capital
4Traction
3ReasonExecuteDataVerifyBiologyProtein designDrug discovery
22
Company
Insitro
Private scaleup · North America · South San Francisco, CA · Founded 2018 · Updated 2025-12
Public deployment6Commercial partnershipsProprietary
Machine-learning drug discovery company founded by Daphne Koller. Builds large biological datasets from in vitro disease models, human genetics, and partnerships to find targets and patient subgroups.
Capital
$600M+ disclosed
$500M+
Runway
Not public
No public cash ledger
Research
1 output
Commercial partnerships
Clinical
0 trials
No registry link
Non-dilutive
0 awards
No tracked grants
Deals
1 deal
Bristol Myers Squibb
Sources
14
linked evidence records
Autonomy
2Execution
3Verification
3Scientific evidence
3Capital
4Traction
3ReasonExecuteDataVerifyBiologyDrug discoveryHuman genetics
23
Company
Iambic Therapeutics
Clinical-stage platform · North America · San Diego, CA · Founded 2019 · Updated 2024-03
Working prototype5Clinical pipelineProprietary
AI-driven small-molecule drug discovery company. Uses multimodal transformers, protein-ligand structure prediction, high-throughput chemistry, and weekly biological data loops to advance candidates.
Capital
$100M
Series B · Oct 2023
Runway
Not public
No public cash ledger
Research
2 outputs
Clinical pipeline
Clinical
1 trial
Phase 1/1b
Non-dilutive
0 awards
No tracked grants
Deals
1 deal
NVIDIA
Sources
13
linked evidence records
Autonomy
3Execution
3Verification
3Scientific evidence
3Capital
3Traction
3ReasonExecuteDataVerifyDrug discoveryChemistryBiology
24
Government lab
Lawrence Livermore National Laboratory
Research facility · North America · Livermore, CA · Founded 1952 · Updated 2025-07
Published results2Research facilityPublic infrastructure
DOE/NNSA national lab applying AI, robotics, and high-performance computing to scientific discovery. APEX is a self-driving alloy-discovery platform for autonomous design, fabrication, and characterization.
Capital
Government
Undisclosed / other
Runway
Not public
No public cash ledger
Research
1 output
Research facility
Clinical
0 trials
No registry link
Non-dilutive
0 awards
No tracked grants
Deals
0 deals
No tracked partnerships
Sources
10
linked evidence records
Autonomy
3Execution
4Verification
3Scientific evidence
4Capital
2Traction
2ReasonExecuteInfrastructureDataVerifyMaterialsAdvanced manufacturingAI for science
25
Frontier AI lab
Anthropic
Frontier platform · North America · San Francisco, CA · Founded 2021 · Updated 2026-04
Working prototype11Frontier platformProprietary
Frontier model developer (Claude family). October 2025 launched Claude for Life Sciences with the Allen Institute and HHMI as founding scientific partners and connectors to Benchling, PubMed, 10x Genomics, ClinicalTrials.gov, and Synapse. April 2026 acquired Coefficient Bio (all-stock, ~$400M) as its first M&A into a new domain. Top of the Ai2 AstaBench scientific-agent leaderboard (Claude Opus 4.7 at 58.0%).
Capital
$10B+ raised across rounds
$500M+
Runway
Not public
No public cash ledger
Research
0 outputs
3 measured results
Clinical
0 trials
No registry link
Non-dilutive
0 awards
No tracked grants
Deals
0 deals
No tracked partnerships
Sources
19
linked evidence records
Autonomy
3Execution
1Verification
3Scientific evidence
3Capital
4Traction
4ReasonVerifyDataBiologyDrug discoveryGeneral scienceReasoning
26
Nonprofit research institute
Ai2
Research platform · North America · Seattle, WA · Founded 2014 · Updated 2026-04
Published results6Open researchOpen
Allen Institute for AI — nonprofit research institute founded by Paul Allen. In August 2025 launched Asta, an open agentic ecosystem for science covering scholarly research assistants, the AstaBench benchmark suite (2,400+ problems across 11 benchmarks), and a developer toolkit with open-source agents, post-trained science LMs, and a 200M-paper Scientific Corpus Tool. AstaBench accepted as ICLR 2026 oral.
Capital
Endowment-backed nonprofit
Undisclosed / other
Runway
Not public
No public cash ledger
Research
0 outputs
Open research
Clinical
0 trials
No registry link
Non-dilutive
0 awards
No tracked grants
Deals
0 deals
No tracked partnerships
Sources
14
linked evidence records
Autonomy
3Execution
1Verification
4Scientific evidence
4Capital
3Traction
3ReasonVerifyDataGeneral scienceLiteratureBiologyReasoning
27
Company
Sakana AI
Private scaleup · Asia-Pacific · Tokyo, Japan · Founded 2023 · Updated 2026-04
Published results6Peer-reviewed demoHybrid
The AI Scientist — autonomous ML research agent. Produces end-to-end research papers with minimal human involvement.
Capital
$135M
Series B · Nov 2025
Runway
Not public
No public cash ledger
Research
4 outputs
Peer-reviewed demo
Clinical
0 trials
No registry link
Non-dilutive
0 awards
No tracked grants
Deals
0 deals
No tracked partnerships
Sources
14
linked evidence records
Autonomy
4Execution
1Verification
2Scientific evidence
3Capital
4Traction
3ReasonVerifyML researchGeneral science
28
Nonprofit lab
FutureHouse
Research platform · North America · San Francisco, CA · Founded 2023 · Updated 2026-04
Published results6Open researchHybrid
Nonprofit AI research lab building autonomous scientists for biology. Released the Crow, Falcon, Owl, and Phoenix agent family, added ether0 and DISCO in 2026, and spun out Edison Scientific in late 2025.
Capital
~$20M grants + $70M spinout seed
<$100M
Runway
Not public
No public cash ledger
Research
3 outputs
2 measured results
Clinical
0 trials
No registry link
Non-dilutive
0 awards
No tracked grants
Deals
0 deals
No tracked partnerships
Sources
14
linked evidence records
Autonomy
4Execution
1Verification
3Scientific evidence
4Capital
2Traction
3ReasonExecuteVerifyDataBiologyLiteratureGeneral science
29
Government lab
PNNL
Research facility · North America · Richland, WA · Founded 1965 · Updated 2026-05
Published results3Research facilityPublic infrastructure
Pacific Northwest National Laboratory. DOE lab with autonomous experimentation programs in chemistry and energy. Part of the DOE × DeepMind Genesis Mission network.
Capital
Government
Undisclosed / other
Runway
Not public
No public cash ledger
Research
2 outputs
Research facility
Clinical
0 trials
No registry link
Non-dilutive
0 awards
No tracked grants
Deals
0 deals
No tracked partnerships
Sources
12
linked evidence records
Autonomy
2Execution
3Verification
3Scientific evidence
4Capital
2Traction
3ExecuteVerifyInfrastructureDataChemistryEnergyMaterials
30
Company
ChemLex
Growth · Asia-Pacific · Singapore · Founded 2022 · Updated 2026-05
Public deployment2CommercialProprietary
AI-for-science startup running a 24/7 autonomous chemistry synthesis line. Serves as the chemistry discovery engine for pharma; global HQ and flagship self-driving lab in Singapore.
Capital
$45M
Growth · Dec 2025
Runway
Not public
No public cash ledger
Research
1 output
Commercial
Clinical
0 trials
No registry link
Non-dilutive
0 awards
No tracked grants
Deals
0 deals
No tracked partnerships
Sources
10
linked evidence records
Autonomy
3Execution
4Verification
2Scientific evidence
2Capital
3Traction
3ReasonExecuteInfrastructureDataChemistryDrug discoveryProgrammable synthesis
31
Academic project
Coscientist (CMU)
Published research · North America · Pittsburgh, PA · Founded 2023 · Updated 2023-12
Published results2Nature paperResearch prototype
Academic autonomous chemistry system from Carnegie Mellon. Uses GPT-4 with tool use, code execution, documentation search, and cloud-lab automation to design, plan, and execute chemistry experiments.
Capital
Academic research
Undisclosed / other
Runway
Not public
No public cash ledger
Research
1 output
Nature paper
Clinical
0 trials
No registry link
Non-dilutive
0 awards
No tracked grants
Deals
0 deals
No tracked partnerships
Sources
10
linked evidence records
Autonomy
4Execution
3Verification
3Scientific evidence
4Capital
1Traction
2ReasonExecuteVerifyDataChemistryAutonomous agentsCloud lab
32
Company
Opentrons
Commercial · North America · New York, NY · Founded 2013 · Updated 2026-05
Public deployment3CommercialHybrid
Open-source liquid-handling robotics company. Flex and OT-2 robots make programmable wet-lab automation accessible through modular hardware, Python APIs, and protocol libraries.
Capital
Private, venture-backed
Undisclosed / other
Runway
Not public
No public cash ledger
Research
1 output
Commercial
Clinical
0 trials
No registry link
Non-dilutive
0 awards
No tracked grants
Deals
0 deals
No tracked partnerships
Sources
10
linked evidence records
Autonomy
2Execution
4Verification
2Scientific evidence
3Capital
2Traction
4ExecuteInfrastructureLab automationBiologyLiquid handling
33
Public company
Tecan
Public · Europe · Maennedorf, Switzerland · Founded 1980 · Updated 2026-05
Public deployment4SIX Swiss Exchange: TECNISIN CH0012100191CommercialCommercial hardware
Swiss public lab-automation and life-science instrumentation company. Fluent and related workstations provide liquid handling, robotics, readers, and process automation across pharma and diagnostics.
Capital
Public (SIX: TECN)
Public
Runway
Pending
Non-SEC public company; SIX/annual-report fields are not yet normalized into public-financials.json.
Research
1 output
Commercial
Clinical
0 trials
No registry link
Non-dilutive
0 awards
No tracked grants
Deals
0 deals
No tracked partnerships
Sources
7
linked evidence records
Autonomy
1Execution
4Verification
2Scientific evidence
3Capital
3Traction
4ExecuteInfrastructureLab automationDiagnosticsLife sciences
34
Company
Genesis Molecular AI
Private scaleup · North America · Burlingame, CA · Founded 2019 · Updated 2026-05
Working prototype4Platform pipelineProprietary
AI-first small-molecule drug discovery company formerly known as Genesis Therapeutics. GEMS combines generative AI, molecular simulation, and predictive models to design molecules for difficult targets.
Capital
$200M
Series B · Aug 2023
Runway
Not public
No public cash ledger
Research
1 output
Platform pipeline
Clinical
0 trials
No registry link
Non-dilutive
0 awards
No tracked grants
Deals
0 deals
No tracked partnerships
Sources
12
linked evidence records
Autonomy
3Execution
2Verification
3Scientific evidence
3Capital
3Traction
3ReasonExecuteDataVerifyDrug discoveryChemistryMolecular AI
35
Company
Automata
Growth · Europe · London, UK · Founded 2015 · Updated 2026-05
Public deployment3CommercialProprietary
Lab-automation operating system for AI-ready wet labs. Modular robotics, orchestration software, and unified data infrastructure to turn physical labs into programmable, repeatable systems.
Capital
$45M
Series C · Jan 2026
Runway
Not public
No public cash ledger
Research
1 output
Commercial
Clinical
0 trials
No registry link
Non-dilutive
0 awards
No tracked grants
Deals
1 deal
Molecular Devices
Sources
10
linked evidence records
Autonomy
2Execution
4Verification
2Scientific evidence
2Capital
2Traction
4ExecuteInfrastructureDataBiologyDiagnosticsLab automation
36
Company
Xaira Therapeutics
Private scaleup · North America · South San Francisco, CA · Founded 2024 · Updated 2026-05
Published results2Published data assetProprietary
AI-driven drug discovery and design company. Uses ML from hypothesis through clinical development.
Capital
$1B
Series A · Apr 2024
Runway
Not public
No public cash ledger
Research
1 output
Published data asset
Clinical
0 trials
No registry link
Non-dilutive
0 awards
No tracked grants
Deals
0 deals
No tracked partnerships
Sources
10
linked evidence records
Autonomy
2Execution
2Verification
3Scientific evidence
3Capital
4Traction
2ReasonDataVerifyBiologyDrug discoveryVirtual cell
37
Company
Edison Scientific
Seed · North America · San Francisco, CA · Founded 2025 · Updated 2026-05
Published results6Launch paperProprietary
Commercial spinout of FutureHouse. Kosmos is a multi-agent AI co-scientist that runs 12-hour cycles of literature review, data analysis, and hypothesis generation — executing ~42,000 lines of code and reading ~1,500 papers per run. Its 2026 surface also includes PaperQA3-backed Edison Literature and LABBench2.
Capital
$70M
Seed · Dec 2025
Runway
Not public
No public cash ledger
Research
1 output
Launch paper
Clinical
0 trials
No registry link
Non-dilutive
0 awards
No tracked grants
Deals
1 deal
NVIDIA
Sources
14
linked evidence records
Autonomy
4Execution
1Verification
3Scientific evidence
3Capital
3Traction
2ReasonVerifyDataBiologyMaterialsStatistical geneticsGeneral science
38
Company
Citrine Informatics
Growth · North America · Redwood City, CA · Founded 2013 · Updated 2023-01
Public deployment3CommercialProprietary
Materials AI platform for chemicals, formulations, and manufactured products. Provides domain-specific data infrastructure and AI models that help R&D teams predict, optimize, and reuse materials knowledge.
Capital
$16M
Series C · Jan 2023
Runway
Not public
No public cash ledger
Research
1 output
Commercial
Clinical
0 trials
No registry link
Non-dilutive
0 awards
No tracked grants
Deals
0 deals
No tracked partnerships
Sources
11
linked evidence records
Autonomy
2Execution
1Verification
3Scientific evidence
3Capital
3Traction
4ReasonDataVerifyMaterialsChemistryManufacturing
39
Company
HighRes Biosolutions
Commercial · North America · Beverly, MA · Founded 2004 · Updated 2026-05
Public deployment4CommercialCommercial hardware and software
Life-science lab automation company combining modular hardware, liquid handling, dynamic scheduling, and Cellario orchestration software for drug discovery, genomics, and synthetic biology workflows.
Capital
Private; Axel Johnson portfolio company
Undisclosed / other
Runway
Not public
No public cash ledger
Research
1 output
Commercial
Clinical
0 trials
No registry link
Non-dilutive
0 awards
No tracked grants
Deals
1 deal
TetraScience
Sources
11
linked evidence records
Autonomy
2Execution
4Verification
2Scientific evidence
2Capital
2Traction
4ExecuteInfrastructureDataLab automationDrug discoverySynthetic biologyGenomics
40
Company
Iktos
Commercial platform · Europe · Paris, France · Founded 2016 · Updated 2025-09
Public deployment5Commercial platformHybrid
Generative AI and robotics platform for small-molecule drug discovery. Makya designs molecules, Spaya plans synthesis routes, and robotics execute synthesis, purification, analysis, and biological testing.
Capital
EUR15.5M Series A plus EIC support
Undisclosed / other
Runway
Not public
No public cash ledger
Research
2 outputs
Commercial platform
Clinical
0 trials
No registry link
Non-dilutive
0 awards
No tracked grants
Deals
0 deals
No tracked partnerships
Sources
13
linked evidence records
Autonomy
3Execution
3Verification
2Scientific evidence
3Capital
2Traction
3ReasonExecuteDataVerifyChemistryDrug discoveryMedicinal chemistry
41
Company
Generare
Series A · Europe · Paris, France · Founded 2023 · Updated 2026-04
Public deployment2Commercial data-generation platformCommercial partnership
Techbio company decoding microbial genomes to express silent chemistry and generate proprietary novel small-molecule data for drug discovery.
Capital
€25M
Series A · Apr 2026
Runway
Not public
No public cash ledger
Research
1 output
Commercial data-generation platform
Clinical
0 trials
No registry link
Non-dilutive
0 awards
No tracked grants
Deals
0 deals
No tracked partnerships
Sources
10
linked evidence records
Autonomy
2Execution
3Verification
2Scientific evidence
3Capital
3Traction
3DataExecuteReasonNatural productsDrug discoverySynthetic biology
42
Academic platform
RoboChem-Flex
Peer-reviewed prototype · Europe · Netherlands · Founded 2026 · Updated 2026-04
Published results1Peer-reviewed prototypeOpen research
Academic low-cost modular self-driving laboratory for automated chemical reaction optimization, with Python control software and Bayesian optimization.
Capital
Academic research
Undisclosed / other
Runway
Not public
No public cash ledger
Research
1 output
Peer-reviewed prototype
Clinical
0 trials
No registry link
Non-dilutive
0 awards
No tracked grants
Deals
0 deals
No tracked partnerships
Sources
9
linked evidence records
Autonomy
3Execution
3Verification
3Scientific evidence
4Capital
1Traction
2ExecuteReasonInfrastructureVerifyChemistryLab automationOptimization
43
Platform initiative
Microsoft Discovery
Preview · North America · Redmond, WA · Founded 2025 · Updated 2026-04
Working prototype4Enterprise previewPreview / enterprise
Microsoft's enterprise agentic R&D platform for hypothesis generation, simulation, analysis, and iterative experimentation across life sciences, materials, semiconductors, and engineering workflows.
Capital
Microsoft-funded preview
Undisclosed / other
Runway
Not public
No public cash ledger
Research
0 outputs
Enterprise preview
Clinical
0 trials
No registry link
Non-dilutive
0 awards
No tracked grants
Deals
0 deals
No tracked partnerships
Sources
12
linked evidence records
Autonomy
3Execution
2Verification
3Scientific evidence
2Capital
4Traction
2ReasonExecuteVerifyDataInfrastructureBiologyChemistryMaterialsSemiconductors
44
Company
Cenevo
Commercial · North America / Europe · United States / United Kingdom · Founded 2025 rebrand · Updated 2026-02
Public deployment2CommercialProprietary
Lab orchestration and informatics platform formed from Labguru and Titian Software. Provides ELN/LIMS, sample management, workflow automation, protocol conversion, and AI agents for regulated labs.
Capital
Private
Undisclosed / other
Runway
Not public
No public cash ledger
Research
0 outputs
Commercial
Clinical
0 trials
No registry link
Non-dilutive
0 awards
No tracked grants
Deals
0 deals
No tracked partnerships
Sources
9
linked evidence records
Autonomy
2Execution
3Verification
2Scientific evidence
2Capital
2Traction
4ExecuteDataInfrastructureBiologyLab automationScientific informatics
45
Company
Strateos
Commercial · North America · San Diego, CA · Founded 2012 · Updated 2026-05
Public deployment1CommercialProprietary
Robotic cloud lab for life sciences. Automated workflows for drug discovery, synthesis, and assays, accessible via API.
Capital
$56M
<$100M
Runway
Not public
No public cash ledger
Research
1 output
Commercial
Clinical
0 trials
No registry link
Non-dilutive
0 awards
No tracked grants
Deals
0 deals
No tracked partnerships
Sources
10
linked evidence records
Autonomy
2Execution
4Verification
2Scientific evidence
2Capital
2Traction
3ExecuteInfrastructureDataBiologyChemistryCloud lab
46
Company
Atinary
Commercial · Europe · Lausanne, Switzerland · Founded 2019 · Updated 2026-02
Public deployment5Commercial hardware and softwareProprietary
Self-driving lab orchestration and execution layer. Runs SDLabs software plus physical Scientific Discovery Factories for chemistry, materials, and pharma R&D teams.
Capital
Undisclosed
Undisclosed / other
Runway
Not public
No public cash ledger
Research
1 output
Commercial hardware and software
Clinical
0 trials
No registry link
Non-dilutive
0 awards
No tracked grants
Deals
0 deals
No tracked partnerships
Sources
13
linked evidence records
Autonomy
3Execution
3Verification
3Scientific evidence
3Capital
1Traction
2ReasonExecuteVerifyDataChemistryMaterialsDrug discovery
47
Company
Fathom Therapeutics
Series A · North America · New York, NY · Founded 2023 · Updated 2026-05
Working prototype4Working prototypeProprietary
Physics- and AI-driven small-molecule drug design company formerly known as Atommap. Microcosmos simulates protein motion and interactions at atomic resolution to guide lab-in-the-loop discovery.
Capital
$47M
Series A · Apr 2026
Runway
Not public
No public cash ledger
Research
1 output
Working prototype
Clinical
0 trials
No registry link
Non-dilutive
0 awards
No tracked grants
Deals
0 deals
No tracked partnerships
Sources
12
linked evidence records
Autonomy
2Execution
2Verification
2Scientific evidence
3Capital
3Traction
3ReasonExecuteDataVerifyDrug discoveryChemistryBiology
48
Company
Synthace
Growth · Europe · London, UK · Founded 2011 · Updated 2026-05
Public deployment3CommercialProprietary
Cloud experiment-design platform for biological R&D. Turns multivariate experiment designs into automation instructions and structured data that can be analyzed and reused.
Capital
$35M
Series C · Nov 2021
Runway
Not public
No public cash ledger
Research
1 output
Commercial
Clinical
0 trials
No registry link
Non-dilutive
0 awards
No tracked grants
Deals
0 deals
No tracked partnerships
Sources
11
linked evidence records
Autonomy
2Execution
3Verification
2Scientific evidence
2Capital
3Traction
3ReasonExecuteDataBiologyExperiment designLab automation
49
Company
TetraScience
Growth · North America · Boston, MA · Founded 2014 · Updated 2026-05
Public deployment5CommercialProprietary
Scientific Data and AI Cloud for life sciences R&D. Replatforms raw instrument and experiment data into engineered, compliant datasets for analytics, automation, and scientific AI.
Capital
$80M
Series B · Apr 2021
Runway
Not public
No public cash ledger
Research
1 output
Commercial
Clinical
0 trials
No registry link
Non-dilutive
0 awards
No tracked grants
Deals
1 deal
HighRes Biosolutions
Sources
12
linked evidence records
Autonomy
2Execution
1Verification
3Scientific evidence
2Capital
3Traction
4DataInfrastructureVerifyScientific dataBiopharmaLab automation
50
Company
Causaly
Growth · Europe · London, UK; San Francisco, CA · Founded 2018 · Updated 2026-05
Public deployment5Commercial platformProprietary
Agentic AI platform for life-sciences R&D. Combines biomedical knowledge graphs, scientific retrieval, and governed agents for target identification, biomarker research, evidence review, and portfolio decisions.
Capital
$60M
Series B · Jul 2023
Runway
Not public
No public cash ledger
Research
1 output
Commercial platform
Clinical
0 trials
No registry link
Non-dilutive
0 awards
No tracked grants
Deals
0 deals
No tracked partnerships
Sources
13
linked evidence records
Autonomy
3Execution
0Verification
3Scientific evidence
2Capital
3Traction
4ReasonVerifyDataBiomedical researchDrug discoveryEvidence synthesis
51
Government initiative
Materials Genome Initiative
Policy and research network · North America · United States · Founded 2011 · Updated 2026-05
Working prototype2Government initiativePublic infrastructure
US federal multi-agency initiative for accelerated materials discovery and deployment. Coordinates infrastructure, data, autonomous experimentation, and policy for materials innovation.
Capital
Government program
Undisclosed / other
Runway
Not public
No public cash ledger
Research
1 output
Government initiative
Clinical
0 trials
No registry link
Non-dilutive
0 awards
No tracked grants
Deals
0 deals
No tracked partnerships
Sources
10
linked evidence records
Autonomy
1Execution
1Verification
3Scientific evidence
4Capital
2Traction
4InfrastructureDataVerifyMaterialsManufacturingPolicyData infrastructure
52
Company
Alloy Therapeutics
Growth · North America · Boston, MA · Founded 2017 · Updated 2026-04
Public deployment2Commercial infrastructureCommercial partnership
Tech-enabled biotech infrastructure and integrated services platform for biologics discovery and development, combining AI, real-world data, and wet-lab execution.
Capital
$40M
Series E · Apr 2026
Runway
Not public
No public cash ledger
Research
0 outputs
Commercial infrastructure
Clinical
0 trials
No registry link
Non-dilutive
0 awards
No tracked grants
Deals
0 deals
No tracked partnerships
Sources
10
linked evidence records
Autonomy
1Execution
3Verification
2Scientific evidence
2Capital
3Traction
4ExecuteDataInfrastructureBiologicsDrug discoveryBiotech infrastructure
53
Platform initiative
Amazon Bio Discovery
Preview · North America · Seattle, WA · Founded 2026 · Updated 2026-04
Working prototype4Enterprise previewPreview / enterprise
AWS's agentic AI application for drug research, announced April 28, 2026. Exposes 40+ biology foundation models, supports custom uploads and fine-tuning, and integrates with CRO and cloud-lab partners (Ginkgo Nebula, Twist Bioscience, with A-Alpha Bio anticipated) so that agents select BioFMs, route candidates to wet-lab partners for synthesis and testing, and return experimental results into the loop on Bedrock.
Capital
Amazon-funded service
Undisclosed / other
Runway
Not public
No public cash ledger
Research
0 outputs
Enterprise preview
Clinical
0 trials
No registry link
Non-dilutive
0 awards
No tracked grants
Deals
0 deals
No tracked partnerships
Sources
12
linked evidence records
Autonomy
3Execution
2Verification
2Scientific evidence
2Capital
4Traction
2ReasonExecuteDataInfrastructureBiologyDrug discovery
54
Company
Autoscience Institute
Seed · North America · San Francisco, CA · Founded 2023 · Updated 2026-05
Published results3Peer-reviewed demoProprietary
Autonomous agents for ML research. Carl ideates and writes papers; Mira embeds new research directly into production ML models.
Capital
$14M
Seed · Mar 2026
Runway
Not public
No public cash ledger
Research
2 outputs
Peer-reviewed demo
Clinical
0 trials
No registry link
Non-dilutive
0 awards
No tracked grants
Deals
0 deals
No tracked partnerships
Sources
11
linked evidence records
Autonomy
4Execution
1Verification
2Scientific evidence
3Capital
2Traction
2ReasonVerifyML research
55
Company
Radical AI
Seed · North America · New York, NY · Founded 2022 · Updated 2026-05
Published results2Open researchHybrid
AI platform for materials discovery. Focus on industrial biomanufacturing and novel functional materials.
Capital
$13.5M
<$100M
Runway
Not public
No public cash ledger
Research
1 output
Open research
Clinical
0 trials
No registry link
Non-dilutive
0 awards
No tracked grants
Deals
0 deals
No tracked partnerships
Sources
10
linked evidence records
Autonomy
3Execution
3Verification
2Scientific evidence
2Capital
2Traction
2ReasonExecuteDataMaterialsSimulation
56
Company
Helical
Seed · Europe · London, UK · Founded 2024 · Updated 2026-05
Public deployment4Production deploymentProprietary
Virtual AI lab for pharma R&D. Converts biological foundation models into reproducible in-silico discovery workflows for target identification, biomarker discovery, and therapeutic design.
Capital
$10M
Seed · Apr 2026
Runway
Not public
No public cash ledger
Research
1 output
Production deployment
Clinical
0 trials
No registry link
Non-dilutive
0 awards
No tracked grants
Deals
0 deals
No tracked partnerships
Sources
12
linked evidence records
Autonomy
3Execution
1Verification
3Scientific evidence
2Capital
2Traction
3ReasonDataVerifyBiologyDrug discoveryBiomarkers
57
Company
Kebotix
Commercial · North America · Cambridge, MA · Founded 2017 · Updated 2026-05
Public deployment2Commercial platformProprietary
Self-driving laboratory company for chemicals and materials discovery. Combines AI planning, robotics, and high-throughput experimentation to shorten materials and molecule optimization loops.
Capital
$11M
Series A · Apr 2020
Runway
Not public
No public cash ledger
Research
1 output
Commercial platform
Clinical
0 trials
No registry link
Non-dilutive
0 awards
No tracked grants
Deals
0 deals
No tracked partnerships
Sources
10
linked evidence records
Autonomy
3Execution
3Verification
2Scientific evidence
2Capital
2Traction
2ReasonExecuteDataMaterialsChemistryGreen chemistry
58
Company
Artificial
Series A · North America · Palo Alto, CA · Founded 2019 · Updated 2026-05
Public deployment2Commercial platformProprietary
Lab orchestration software for life sciences R&D. Connects wet-lab instruments, informatics systems, scheduling, digital twins, and AI agents into controlled scientific workflows.
Capital
$22M
Series A · May 2021
Runway
Not public
No public cash ledger
Research
1 output
Commercial platform
Clinical
0 trials
No registry link
Non-dilutive
0 awards
No tracked grants
Deals
0 deals
No tracked partnerships
Sources
9
linked evidence records
Autonomy
3Execution
3Verification
2Scientific evidence
2Capital
2Traction
2ExecuteInfrastructureDataLab automationBiologySynthetic biology
59
Company
Cellarity
Private scaleup · North America · Somerville, MA · Founded 2017 · Updated 2025-10
Working prototype6Platform pipelineProprietary
Flagship Pioneering company developing cell-state-correcting medicines. Uses single-cell technologies, network biology, and machine learning to map disease cell behavior and design interventions.
Capital
$121M
Series C · Oct 2022
Runway
Not public
No public cash ledger
Research
2 outputs
Platform pipeline
Clinical
0 trials
No registry link
Non-dilutive
0 awards
No tracked grants
Deals
1 deal
Novo Nordisk
Sources
14
linked evidence records
Autonomy
2Execution
2Verification
3Scientific evidence
2Capital
3Traction
2ReasonDataVerifyBiologyDrug discoverySingle-cell biology
60
Company
Converge Bio
Series A · North America / Middle East · Boston, MA / Tel Aviv, Israel · Founded 2024 · Updated 2026-01
Public deployment2Commercial tractionCommercial partnership
Generative AI platform for drug discovery and development, spanning target discovery, antibody design, and protein manufacturing optimization.
Capital
$25M
Series A · Jan 2026
Runway
Not public
No public cash ledger
Research
0 outputs
Commercial traction
Clinical
0 trials
No registry link
Non-dilutive
0 awards
No tracked grants
Deals
0 deals
No tracked partnerships
Sources
10
linked evidence records
Autonomy
2Execution
1Verification
2Scientific evidence
2Capital
3Traction
3ReasonDataVerifyBiologyDrug discoveryProtein engineering
61
Company / product line
Riffyn
Commercial · North America · Oakland, CA · Founded 2014 · Updated 2026-05
Public deployment2CommercialProprietary
Scientific process design and data platform now offered as Riffyn X inside Siemens. Captures experimental methods, sample lineage, and process data in forms ready for analysis and machine learning.
Capital
$15M
Series B · May 2019
Runway
Not public
No public cash ledger
Research
1 output
Commercial
Clinical
0 trials
No registry link
Non-dilutive
0 awards
No tracked grants
Deals
0 deals
No tracked partnerships
Sources
10
linked evidence records
Autonomy
1Execution
1Verification
3Scientific evidence
2Capital
2Traction
3DataVerifyInfrastructureBioprocessingScientific dataExperiment design
62
Company
10x Science
Seed · North America · San Francisco, CA · Founded 2025 · Updated 2026-05
Working prototype5Announced platformProprietary
AI-native platform for next-generation protein characterization. Automates mass-spectrometry interpretation so biologic drug candidates can be characterized and quality-assessed faster.
Capital
$5M
Seed · Apr 2026
Runway
Not public
No public cash ledger
Research
1 output
Announced platform
Clinical
0 trials
No registry link
Non-dilutive
0 awards
No tracked grants
Deals
0 deals
No tracked partnerships
Sources
14
linked evidence records
Autonomy
2Execution
1Verification
3Scientific evidence
2Capital
1Traction
2DataVerifyBiologyDrug discoveryProtein characterization
63
Company
Thesis
Seed · North America · San Francisco, CA · Founded 2025 · Updated 2026-05
Published results2Benchmark resultProprietary
Applied research lab automating parts of the ML research workflow — experiment planning, training, evaluation, iteration.
Capital
~$3M
<$100M
Runway
Not public
No public cash ledger
Research
1 output
Benchmark result
Clinical
0 trials
No registry link
Non-dilutive
0 awards
No tracked grants
Deals
0 deals
No tracked partnerships
Sources
10
linked evidence records
Autonomy
3Execution
1Verification
2Scientific evidence
2Capital
1Traction
1ReasonVerifyML research
64
Frontier AI lab
AMI Labs
Seed · Europe · Paris, France · Founded 2025 · Updated 2026-05
Working prototype2Announced labProprietary
Advanced Machine Intelligence — Yann LeCun's new lab. Building world models based on Joint Embedding Predictive Architecture (JEPA) rather than next-token LLMs; aims to learn from physical reality as the path to human-level intelligence.
Capital
$1.0B
Seed · Mar 2026
Runway
Not public
No public cash ledger
Research
1 output
Announced lab
Clinical
0 trials
No registry link
Non-dilutive
0 awards
No tracked grants
Deals
0 deals
No tracked partnerships
Sources
10
linked evidence records
Autonomy
2Execution
1Verification
1Scientific evidence
1Capital
4Traction
1ReasonDataWorld modelsGeneral intelligencePhysical reasoning
65
Company
Scivity Labs
Pre-seed · Europe · Yerevan, Armenia · Founded 2025 · Updated 2026-04
Working prototype3Self-reported platformProprietary
Autonomous science platform focused on computational research workflows that design, execute, and verify scientific work end-to-end, with public emphasis on validation outcomes and evidence surfaces.
Capital
Pre-seed, undisclosed
Undisclosed / other
Runway
Not public
No public cash ledger
Research
0 outputs
Self-reported platform
Clinical
0 trials
No registry link
Non-dilutive
0 awards
No tracked grants
Deals
0 deals
No tracked partnerships
Sources
11
linked evidence records
Autonomy
3Execution
2Verification
2Conservative score: public materials describe validation outcomes while thresholds, calibration, and check-composition logic remain private.
Scientific evidence
1Capital
1Traction
1ReasonExecuteVerifyInfrastructureML researchBiologyChemistryGeneral science
66
Company
Tetsuwan Scientific
Pre-seed · North America · San Francisco, CA · Founded 2023 · Updated 2024-11
Working prototype4PilotProprietary
Execution-layer startup building ResearchOS and a future cloud lab so researchers or AI agents can translate natural-language procedures into machine-ready wet-lab workflows.
Capital
$3M
Pre-seed · Apr 2024
Runway
Not public
No public cash ledger
Research
0 outputs
Pilot
Clinical
0 trials
No registry link
Non-dilutive
0 awards
No tracked grants
Deals
0 deals
No tracked partnerships
Sources
12
linked evidence records
Autonomy
2Execution
3Verification
1Scientific evidence
1Capital
1Traction
2ReasonExecuteInfrastructureBiologyLab automationCloud lab
67
Company
Zeon Systems
Seed · North America · San Francisco, CA · Founded 2025 · Updated 2026-05
Working prototype2PilotProprietary
Natural-language-to-robot-arm layer for lab automation. Scientists type protocols in English; software programs off-the-shelf robotics to execute them.
Capital
$0.5M
<$100M
Runway
Not public
No public cash ledger
Research
1 output
Pilot
Clinical
0 trials
No registry link
Non-dilutive
0 awards
No tracked grants
Deals
0 deals
No tracked partnerships
Sources
9
linked evidence records
Autonomy
2Execution
3Verification
1Scientific evidence
1Capital
1Traction
1ExecuteInfrastructureLab automationBiology
Timeline
Capital, claims,
and corrections.
The timeline combines company milestones, field-wide events, and ecosystem capital signals. Cross-market events stay separate from company funding so charts and foreign keys remain clean.
Apr 2026Featured
DOE ARPA-E CATALCHEM-E awards $34M to 12 AI + self-driving lab projects
First large federal bet explicitly tying autonomous labs to industrial catalyst development. Targets compressing catalyst discovery from ~10 years to ~1 year across universities and national labs.
Apr 2026Featured
OpenAI launches GPT-Rosalind for life sciences research
OpenAI introduced GPT-Rosalind on April 16, a frontier reasoning model tuned for biology, drug discovery, and translational medicine, alongside a Codex life-sciences plugin connecting to 50+ scientific tools. Available as a research preview through OpenAI's trusted access program with Amgen, Moderna, Thermo Fisher, and the Allen Institute as launch partners.
Feb 2026Featured
GPT-5 drives 36,000 CFPS experiments in Ginkgo Cloud Lab
OpenAI and Ginkgo reported a closed-loop autonomous CFPS optimization study on February 5: GPT-5 designed experiments, Ginkgo's Cloud Lab executed them with minimal human intervention, results returned to GPT-5, and the next round was proposed by the model. The campaign covered 36,000+ unique reaction compositions across 580 automated plates, six closed-loop rounds, about 40% lower sfGFP production cost, and a 27% titer increase.
Feb 2026Featured
Atinary opens Boston self-driving lab
Atinary announced its Boston AI-powered lab with two autonomous Scientific Discovery Factories running closed-loop Design-Make-Test-Analyze-Learn cycles. The lab integrates Atinary's no-code AI platform with robotics and instruments from ABB, Agilent, Bruker, Chemspeed, and Mettler-Toledo for small-molecule synthesis and catalysis.
May 2026
Milestone
Recursion Q1 2026: REC-4881 establishes clinical proof of concept in FAP
Recursion's Q1 2026 results, reported May 6, established clinical proof of concept for REC-4881 in familial adenomatous polyposis with significant precancerous polyp reduction; Recursion has initiated FDA engagement for a potential registrational study. The company also booked a fifth Sanofi milestone payment on a partnered first-in-class oncology program and reaffirmed runway into early 2028.
May 2026
Milestone
Ginkgo positions Nebula as its autonomous-lab core
Ginkgo's Q1 2026 results, reported May 7, highlighted Cloud Lab adoption from ProQR and Amazon's Bio Discovery platform. Jason Kelly positioned Nebula as the world's largest autonomous lab and targeted doubling the Nebula footprint in 2026. Q1 revenue was $19M with $373M in cash, cash equivalents and marketable securities.
May 2026
Milestone
Edison Scientific publishes LABBench2 biology research benchmark
Edison Scientific released LABBench2 on May 2, a 1,892-task benchmark spanning literature, databases, sequences, protocols, patents, trials, and source quality across 11 task families. Moves agent evaluation from short-form biology recall toward practical research workflows including retrieval, file handling, and tool use.
May 2026
Milestone
Eli Lilly / Profluent strike $2.25B AI recombinase pact
Eli Lilly and Profluent announced a multi-program strategic research collaboration to design and commercialize custom site-specific recombinases for severe-unmet-need diseases. Deal carries an upfront payment, committed R&D funding, up to $2.25B in development and commercial milestones, and tiered royalties on net sales.
Apr 2026
Company funding
Helical: $10M Seed
Seed round for a virtual AI lab that turns biological foundation models into reproducible in-silico pharma R&D workflows.
Apr 2026
Company funding
10x Science: $4.8M Seed
Seed round to build AI-native protein characterization for the verification bottleneck in biologic drug development.
Apr 2026
Company funding
Fathom Therapeutics: $47M Series A
Series A for Microcosmos, a physics- and AI-driven small-molecule design platform with lab-in-the-loop discovery programs.
Apr 2026
Ecosystem event
DOE ARPA-E CATALCHEM-E: Government grants · $34M
12 projects pairing AI with self-driving labs to compress catalyst-development timelines from ~10 years to ~1 year. Recipients include NC State ($2.99M), UW-Madison ($2.84M), Ames National Lab ($2.52M).
Apr 2026
Ecosystem event
Anthropic / Coefficient Bio: Acquisition · ~$400M
All-stock. First Anthropic M&A into a new domain. ~10 employees, ~$40M+ per employee. Stanton + Frey (ex-Prescient Design). Dimension VC reportedly 38,513% IRR.
Apr 2026
Ecosystem event
ProQR / Ginkgo Bioworks: Partnership · undisclosed
ProQR gained access to Ginkgo's Nebula autonomous lab for high-throughput data generation supporting Axiomer RNA-editing discovery. Ginkgo also made a strategic equity investment in ProQR.
Apr 2026
Ecosystem event
ARIA Activation Partners: Government program · 100M GBP (~$125M) open call
ARIA opened a 100M GBP call for 8-10 Activation Partners, explicitly adding AI-for-science tools, AI Scientist systems, and autonomous labs as capabilities to bring into ARIA-funded R&D. Open call ceiling, not yet committed awards — excluded from capital totals.
Apr 2026
Ecosystem event
Project Prometheus: physical-AI capital signal · $10B (adjacent, physical-AI)
Bloomberg-cited reporting said Project Prometheus closed a roughly $10B round at about a $38B valuation for a physical-AI lab focused on engineering and manufacturing physical products. Tracked as an adjacent ecosystem signal for context, not autonomous-science capital — excluded from capital totals.
Apr 2026
Milestone
Anthropic acquires Coefficient Bio
All-stock, ~$400M. First Anthropic M&A into a new domain. Signals that frontier labs will enter AI-for-science domain-by-domain through acqui-hires.
Apr 2026
Milestone
OpenAI publishes Industrial Policy paper
Calls for 'distributed AI-enabled laboratories' as public infrastructure. Commits $100K grants + $1M API credits, not capital to build the network.
Apr 2026
Milestone
DOE ARPA-E CATALCHEM-E awards $34M to 12 AI + self-driving lab projects
First large federal bet explicitly tying autonomous labs to industrial catalyst development. Targets compressing catalyst discovery from ~10 years to ~1 year across universities and national labs.
Apr 2026
Milestone
Sakana AI launches Marlin closed beta
First commercial product from Sakana. Autonomous enterprise research agent (Adaptive Branching MCTS + AI Scientist workflow) producing slide decks and multi-dozen-page reports in one 8-hour run — the AI Scientist architecture repurposed for corporate strategy.
Apr 2026
Milestone
Chemify publishes three chemputation validation papers
Cronin/Chemify published three peer-reviewed papers in PNAS and Nature Communications sister journals validating the chemputer for autonomous drug synthesis and kinase inhibitor discovery.
Apr 2026
Milestone
Stanford AI Index 2026: AI agents trail PhD scientists on complex tasks
Stanford HAI's 2026 AI Index Report (released April 13) found that the best frontier AI agents score roughly half as well as human PhDs on complex multi-step scientific workflows, even as models passed the PhD-expert baseline on GPQA. A Nature commentary framed it as the field's first quantitative reality check on autonomous-science agents.
Apr 2026
Milestone
FutureHouse introduces DISCO enzyme design model
FutureHouse, Caltech, Mila, and collaborators introduced DISCO, a multimodal generative model that co-designs protein sequence and structure. The team reported functional new-to-nature carbene-transfer enzymes, including a B-H insertion design reaching 98% product and 5,170 total turnovers.
Apr 2026
Milestone
Sakana AI opens Fugu multi-agent beta
Sakana AI introduced Fugu, a multi-agent orchestration system that learns to route work across frontier foundation models and itself. Sakana frames the beta as an API product for coding, mathematics, and scientific-reasoning workloads.
Apr 2026
Milestone
Agent4Science launches as agents-only research social network
University of Chicago's Chenhao Tan launched Agent4Science, a Reddit-style site where AI agents share, debate, and review papers — including AI-generated ones — while humans can only observe. An early experiment in agent-to-agent scientific discourse described in Nature on April 20.
Apr 2026
Milestone
Isomorphic Labs publicly preparing first-in-human AI-designed drug trials
Speaking at WIRED Health on April 16, Isomorphic Labs president Max Jaderberg confirmed the AlphaFold-derived oncology pipeline is gearing up to enter the clinic, the first major operational signal that an AI-native drug-discovery program is reaching first-in-human studies.
Apr 2026
Milestone
OpenAI launches GPT-Rosalind for life sciences research
OpenAI introduced GPT-Rosalind on April 16, a frontier reasoning model tuned for biology, drug discovery, and translational medicine, alongside a Codex life-sciences plugin connecting to 50+ scientific tools. Available as a research preview through OpenAI's trusted access program with Amgen, Moderna, Thermo Fisher, and the Allen Institute as launch partners.
Apr 2026
Milestone
Google DeepMind launches Deep Research and Deep Research Max
Google DeepMind released Deep Research and Deep Research Max in public preview on April 21, autonomous research agents built on Gemini 3.1 Pro that combine open-web search with private data via Model Context Protocol. Deep Research Max runs roughly 160 search queries per task, targeting long-horizon research workflows.
Apr 2026
Milestone
OpenAI releases GeneBench scientific-agent benchmark
OpenAI released GeneBench on April 23, a benchmark of 103 multi-stage scientific data analysis tasks across 10 genomics and quantitative biology domains. Frontier models score around 25-33%, with OpenAI noting that individual tasks often correspond to multi-day projects for expert computational biologists.
Apr 2026
Milestone
Ginkgo closes Biosecurity divestiture to Tower Biosecurity
On April 3, 2026, Ginkgo completed the divestiture of substantially all Biosecurity-segment operations to Tower Biosecurity, also known as Perimeter Systems, receiving common stock representing about 20% of the purchaser on a fully diluted basis and refocusing the company around autonomous labs.
Apr 2026
Milestone
MGI releases autonomous experimentation materials R&D report
The Materials Genome Initiative published an autonomous experimentation report summarizing AMII workshop findings and next steps for accelerated materials R&D.
Apr 2026
Milestone
Ai2 updates AstaBench scientific-agent leaderboard
Ai2's spring 2026 AstaBench update reported new frontier-model results on a suite of 2,400+ scientific research problems spanning literature understanding, coding and execution, data analysis, and end-to-end discovery.
Apr 2026
Milestone
RoboChem-Flex publishes affordable modular self-driving lab
Nature Synthesis published RoboChem-Flex, a low-cost modular self-driving laboratory for autonomous reaction optimization with Python software, Bayesian optimization, closed-loop and human-in-the-loop modes, and six validation case studies.
Apr 2026
Milestone
Generare raises €20M Series A for microbial chemistry platform
Generare raised a €20M Series A co-led by Alven and Daphni to scale its platform for reading microbial genomes, expressing silent chemistry, and generating proprietary novel small-molecule data.
Apr 2026
Milestone
Alloy Therapeutics raises $40M Series E at $1B valuation
Alloy raised a $40M Series E at a $1B valuation, reporting 200+ partners, 100+ licensed therapeutic programs, 22 clinical programs, and positioning its AI, real-world-data, and wet-lab capabilities as on-demand biotech infrastructure.
Apr 2026
Milestone
Scivity discloses first end-to-end autonomous research run
Scivity reported an autonomous research run spanning experiment design, execution, verification, and report generation without human intervention.
Apr 2026
Milestone
Microsoft expands Discovery preview with enterprise R&D partners
Microsoft expanded preview access for Discovery, adding partner integrations, customer examples, and explicit interoperability with physical labs, robotics, and HPC-backed R&D workflows.
Apr 2026
Milestone
Anthropic releases BioMysteryBench for bioinformatics research
Anthropic introduced BioMysteryBench, a 99-task bioinformatics evaluation with expert baselines and reliability analysis, alongside Claude evaluations on the dataset.
Apr 2026
Milestone
AWS launches Amazon Bio Discovery agentic drug-research platform
AWS announced Amazon Bio Discovery on April 28: agentic AI on Bedrock that selects from 40+ biology foundation models, routes candidates to integrated CRO and cloud-lab partners (Ginkgo Nebula, Twist Bioscience, A-Alpha Bio anticipated) for synthesis and testing, and returns results into a lab-in-the-loop cycle. Early Memorial Sloan Kettering project triaged 300,000 antibody candidates in weeks.
Mar 2026
Company funding
Autoscience Institute: $14M Seed
Toyota Ventures, Perplexity Fund, S32, MaC participated. Commercial launch of Carl and Mira agents.
Methodology
Comparable data,
without false precision.
Included entities must materially affect autonomous scientific discovery: reasoning systems, wet-lab or dry-lab execution layers, scientific verification, domain data loops, or infrastructure that makes autonomous research deployable.
Pure AI infrastructure providers, broad model labs, and general AGI benchmarks are included only when they have a clear science-relevant signal. The aim is a science-first AGI-progress lens, not a general model directory.
Dimensional scoring
Autonomy
How much of the scientific workflow can run without human step-by-step operation.
Execution
Whether the system can touch the physical world, run labs, trigger assays, or operate production scientific workflows.
Verification
How directly the system can evaluate, reproduce, critique, or measure scientific claims.
Scientific evidence
Strength of public evidence: papers, clinical data, benchmark results, open artifacts, or deployed research outputs.
Capital
Scale of committed capital, strategic partnerships, public-market access, or institutional funding.
Traction
Commercial, institutional, research, or user adoption signals beyond a launch announcement.
Source policy
Every entity, funding event, milestone, ecosystem event, benchmark definition, and measured benchmark result carries source IDs. The validator checks provenance links, date shape, foreign keys, score ranges, and measured-result baselines.
v1 is manually curated. Codex automations and recurring refresh flows are intentionally deferred until the data contract is stable.
Data and citation
Funding totals exclude valuation-only discussions and milestone-contingent “up to” amounts. Cross-market events are stored separately from company funding to keep company foreign keys clean.
This page is free to reuse under Creative Commons BY 4.0. Citation: Scivity Labs (2026), “The AI for Science Landscape,” scivity.org/landscape.
Full dataset: JSON · entity CSV. Table CSVs: funding · financials · research · benchmark results · deals · trials. Machine-readable summary for AI agents: llms.txt.
314 source records are currently tracked.
Last updated · May 202626 benchmark/progress records36 measured benchmark resultsCC BY 4.0 citation-ready dataset